NNC 0519 0130
Alternative Names: NNC-0519-0130Latest Information Update: 27 Aug 2024
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 07 Aug 2024 Novo Nordisk initiates enrolment in a phase-I trial for Type 2 diabetes mellitus in Germany (SC), (NCT06567041)
- 07 Aug 2024 Novo Nordisk initiates enrolment in a phase-I trial for Obesity in Germany (SC), (NCT06567041)
- 18 Jul 2024 Novo Nordisk initiates a phase I pharmacokinetics trial (In volunteers) in Germany (SC) (NCT06513104) (EudraCT2023-507973-16)